Deciphera Pharmaceuticals. has filed a patent for methods of treating cancers and tumors by targeting tumor-associated macrophages (TAMs), including TGCT and DTGCT. The claim includes specific methods for depleting or repolarizing TAMs. GlobalData’s report on Deciphera Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Deciphera Pharmaceuticals Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Deciphera Pharmaceuticals, Cancer treatment biomarkers was a key innovation area identified from patents. Deciphera Pharmaceuticals's grant share as of January 2024 was 27%. Grant share is based on the ratio of number of grants to total number of patents.

Treatment of cancers by targeting tumor-associated macrophages

Source: United States Patent and Trademark Office (USPTO). Credit: Deciphera Pharmaceuticals Inc

A recently filed patent (Publication Number: US20230414614A1) outlines a method for treating tenosynovial giant cell tumors in patients. The method involves administering a therapeutically effective amount of a specific compound to the patient. The patent specifies various dosages and durations for the treatment, ranging from 2 mg to 60 mg of the compound twice weekly for periods of 3 months to 2 years. The method is particularly targeted towards benign tenosynovial giant cell tumors, including the diffuse-type variant.

Furthermore, the patent details a specific treatment regimen involving the administration of 30 mg of the compound twice weekly for varying durations, depending on the patient's condition. This method is also focused on treating benign tenosynovial giant cell tumors, specifically the diffuse-type variant. The dosages and treatment durations outlined in the patent aim to provide a comprehensive approach to effectively managing these tumors in patients in need of treatment. Overall, the patent offers a structured and detailed method for addressing tenosynovial giant cell tumors, emphasizing the importance of the specific compound and treatment regimen in achieving positive outcomes for patients.

To know more about GlobalData’s detailed insights on Deciphera Pharmaceuticals, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies